Emerging Biopharma

We Are Immersed In A New Era Of Drug Discovery – And A Revolution In Financing.

Locust Walk links visionary investors and partners with transformative opportunities in emerging biopharma – while providing vital leadership and deal acumen for company growth.

Tomorrow’s great pharmaceutical breakthroughs will come from today’s emerging biopharma firms. At a time when the growth of large pharmaceutical companies is stalling, a wave of scientific discovery is fueling the rise of a new class of biopharma firms.

These young firms must carve a new path, as a decade of poor returns for the asset class has reduced the amount of traditional institutional venture capital available.

Enter Locust Walk.

Our seasoned industry executives contribute specific, relevant operating experience – empowering small biopharma companies by providing them with hands-on expertise, connectivity with potential funding sources and strategic partners, and deep analytical capability. We are distinguished by our rigorous assessment of commercial value and by the continuity we foster – paralleling process discussions with strategic partners and potential investors to maximize options for companies.

Locust Walk provides exciting new companies with the guidance and resources required to hit strategic growth benchmarks and fulfill their technological and market potential.

Our team’s deep industry experience enables us to help emerging biopharma firms scale up through rigorous assessment and analysis, connectivity with funding sources and strategic partners, and hands-on operational support.

Business & Corporate Development

Financing & IPO Advisory

OVERVIEW

  • Business case development
  • Targeted partner outreach
  • Due diligence staging
  • Deal structuring and evaluation
  • Contract negotiations

RESULTS

  • Data-driven approach
  • Structured process
  • Competitive tension and bidding
  • Real-time negotiations
  • Maximum deal value

OVERVIEW

  • Commercial assessment
  • Investor materials preparation
  • Targeted investor outreach
  • Due diligence staging
  • Deal comparables
  • Introductions to bankers and research analysts
  • S1 drafting (business section)

RESULTS

  • Robust understanding of opportunity
  • Succinct presentations
  • Relevant Investors
  • Competitive process
  • Realistic valuation and optimal outcome

Locust Walk provides exciting new companies with the guidance and resources required to hit strategic growth benchmarks and fulfill their technological and market potential.

Our team’s deep industry experience enables us to help emerging biopharma firms scale up through rigorous assessment and analysis, connectivity with funding sources and strategic partners, and hands-on operational support.

Business & Corporate Development

OVERVIEW

  • Business case development
  • Targeted partner outreach
  • Due diligence staging
  • Deal structuring and evaluation
  • Contract negotiations

Business & Corporate Development

RESULTS

  • Data-driven approach
  • Structured process
  • Competitive tension and bidding
  • Real-time negotiations
  • Maximum deal value

Financing & IPO Advisory

OVERVIEW

  • Commercial assessment
  • Investor materials preparation
  • Targeted investor outreach
  • Due diligence staging
  • Deal comparables
  • Introductions to bankers and research analysts
  • S1 drafting (business section)

Financing & IPO Advisory

RESULTS

  • Robust understanding of opportunity
  • Succinct presentations
  • Relevant Investors
  • Competitive process
  • Realistic valuation and optimal outcome

Locust Walk provides exciting new companies with the guidance and resources required to hit strategic growth benchmarks and fulfill their technological and market potential.

Our team’s deep industry experience enables us to help emerging biopharma firms scale up through rigorous assessment and analysis, connectivity with funding sources and strategic partners, and hands-on operational support.

Business & Corporate Development

OVERVIEW

  • Business case development
  • Targeted partner outreach
  • Due diligence staging
  • Deal structuring and evaluation
  • Contract negotiations

RESULTS

  • Data-driven approach
  • Structured process
  • Competitive tension and bidding
  • Real-time negotiations
  • Maximum deal value

Financing & IPO Advisory

OVERVIEW

  • Commercial assessment
  • Investor materials preparation
  • Targeted investor outreach
  • Due diligence staging
  • Deal comparables
  • Introductions to bankers and research analysts
  • S1 drafting (business section)

RESULTS

  • Robust understanding of opportunity
  • Succinct presentations
  • Relevant Investors
  • Competitive process
  • Realistic valuation and optimal outcome

Emerging Biopharma Transaction Highlights

THAR-LOGO-1-300x110

CLIENT: Thar Pharmaceuticals

TRANSACTION:
Multi-Track Sell-Side and Financing Engagement Leading to Acquisition

View case study »

Stonebridge_Logo_Website

CLIENT: Strongbridge Biopharma

PARTNER: Investors

TRANSACTION:

Private Placement of $26.4M

View press release »

Locust_Fabrus_Senesco

CLIENT: Fabrus

PARTNER: Senesco

TRANSACTION:
Merger between Fabrus and Senesco Technologies

View case study »

Locust_Strategic

CLIENT: Strategic Science & Technologies, LLC

PARTNER: Undisclosed

TRANSACTION:
Worldwide Licensing Agreement for IbuCream (topical ibuprofen)

View case study »

CLIENT: Strongbridge Biopharma

TRANSACTION:
Raised $25M in a U.S. initial public offering issuing 2,500,000 shares at $10 per share

View case study »

Locust_Strategic

CLIENT: Strategic Science & Technologies, LLC

PARTNER: Global OTC Player

TRANSACTION:
US Option Agreement for IbuCream (topical ibuprofen)

View case study »

Locust_Ascenta_Debiopharm

CLIENT: Ascenta

PARTNER: Debiopharm Group

TRANSACTION:
Worldwide Licensing Agreement for AT-406

View case study »

Locust_Concordian_Ono

CLIENT: Concordia Pharmaceuticals

PARTNER: Ono

TRANSACTION:
Licensing Agreement for Salirasib in Japan

View case study »

CLIENT: Strongbridge Biopharma

PARTNER: Investors

TRANSACTION:
Private Placement of $33.2M

View case study »

Locust_Teso_Aspen

CLIENT: TesoRx

PARTNER: Aspen

TRANSACTION:
Regional License Agreement and Investment for an Oral Unmodified Testosterone Replacement.

View case study »

Locust_Angio_Geron

CLIENT: Angiochem

PARTNER: Geron

TRANSACTION: Worldwide Licensing Agreement for ANG1005 and Research Collaboration for Telomerase

View case study »

Locust_Armetheon

CLIENT: Armetheon

PARTNER: Investors

TRANSACTION:
Series B Financing of 24M

View press release »

Locust_Armetheon

CLIENT: Armetheon

PARTNER: Investors

TRANSACTION:
Series A Financing of $7M

View press release »

Locust_Synthetic_Novartis

CLIENT: Synthetic Genomics

PARTNER: Novartis

TRANSACTION:
Advisor in Forming New Company Synthetic Genomics Vaccines Inc. and Advisor on Structuring

View case study »